Vera Therapeutics (VERA) Stock: Why It's Up Today
Updated Oct 19, 2026, 4:00 PM ET · closing price
- Closed at $28.92, +3.73% vs the prior close of $27.88.
- Volume 1.27M shares, 0.6x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
VERA jumps 3.7% to $28.92. Closed at $28.92, +3.73% vs the prior close of $27.88. Day range $27.61–$29.23, opened at $28.18.
VERA daily analysis — what happened
A plain-English, data-only note for every US trading day (today's note updates every 2 hours while the market is open). Newest first; older days stay archived below.
Oct 19, 2026 — VERA jumps 3.7% to $28.92
- Closed at $28.92, +3.73% vs the prior close of $27.88. Day range $27.61–$29.23, opened at $28.18.
- Volume was 1.27M shares, 0.6x its 50-day average of 2.19M — lighter than usual.
- Price is -10.2% vs its 50-day average ($32.22) and -23.4% vs its 200-day average ($37.77).
- 52-week range $23.05–$56.05; today's close sits at 18% of that range, 48.4% below the 52-week high.
Oct 16, 2026 — VERA dips 2.4% to $27.88
- Closed at $27.88, -2.42% vs the prior close of $28.57. Day range $27.50–$28.37, opened at $28.30.
- Volume was 1.29M shares, 0.6x its 50-day average of 2.21M — lighter than usual.
- Price is -13.7% vs its 50-day average ($32.29) and -26.4% vs its 200-day average ($37.88).
- 52-week range $23.05–$56.05; today's close sits at 15% of that range, 50.3% below the 52-week high.
Oct 15, 2026 — VERA jumps 6.8% to $28.57
- Closed at $28.57, +6.84% vs the prior close of $26.74. Day range $27.13–$28.83, opened at $27.28.
- Volume was 1.53M shares, 0.7x its 50-day average of 2.24M.
- Price is -11.8% vs its 50-day average ($32.38) and -24.8% vs its 200-day average ($37.99).
- 52-week range $23.05–$56.05; today's close sits at 17% of that range, 49.0% below the 52-week high.
Oct 14, 2026 — VERA ends flat (-0.2%) to $26.74, a 6-month low, 3 down days in a row
- Closed at $26.74, -0.19% vs the prior close of $26.79. Day range $26.38–$27.42, opened at $26.84.
- Volume was 1.53M shares, 0.7x its 50-day average of 2.31M.
- Price is -17.5% vs its 50-day average ($32.41) and -29.8% vs its 200-day average ($38.11).
- 52-week range $23.05–$56.05; today's close sits at 11% of that range, 52.3% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — VERA slides 3.4% to $26.79, a 6-month low
- Closed at $26.79, -3.35% vs the prior close of $27.72. Day range $26.55–$27.73, opened at $27.62.
- Volume was 2.99M shares, 1.3x its 50-day average of 2.28M.
- Price is -17.5% vs its 50-day average ($32.48) and -30.0% vs its 200-day average ($38.24).
- 52-week range $23.05–$56.05; today's close sits at 11% of that range, 52.2% below the 52-week high.
Oct 12, 2026 — VERA slides 7.2% to $27.72, a 6-month low
- Closed at $27.72, -7.23% vs the prior close of $29.88. Day range $27.64–$29.49, opened at $29.11.
- Volume was 1.41M shares, 0.6x its 50-day average of 2.28M.
- Price is -14.9% vs its 50-day average ($32.59) and -27.8% vs its 200-day average ($38.39).
- 52-week range $23.05–$56.05; today's close sits at 14% of that range, 50.5% below the 52-week high.
Oct 9, 2026 — VERA rises 0.5% to $29.88
- Closed at $29.88, +0.50% vs the prior close of $29.73. Day range $29.46–$30.51, opened at $29.57.
- Volume was 996.60K shares, 0.4x its 50-day average of 2.31M — lighter than usual.
- Price is -8.6% vs its 50-day average ($32.67) and -22.4% vs its 200-day average ($38.52).
- 52-week range $23.05–$56.05; today's close sits at 21% of that range, 46.7% below the 52-week high.
Oct 8, 2026 — VERA dips 1.7% to $29.73
- Closed at $29.73, -1.72% vs the prior close of $30.25. Day range $28.74–$30.25, opened at $30.00.
- Volume was 1.73M shares, 0.8x its 50-day average of 2.30M.
- Price is -9.2% vs its 50-day average ($32.74) and -23.1% vs its 200-day average ($38.64).
- 52-week range $23.05–$56.05; today's close sits at 20% of that range, 47.0% below the 52-week high.
Oct 7, 2026 — VERA rises 2.8% to $30.25
- Closed at $30.25, +2.82% vs the prior close of $29.42. Day range $28.46–$30.61, opened at $29.09.
- Volume was 3.29M shares, 1.4x its 50-day average of 2.30M.
- Price is -7.8% vs its 50-day average ($32.79) and -21.9% vs its 200-day average ($38.75).
- 52-week range $23.05–$56.05; today's close sits at 22% of that range, 46.0% below the 52-week high.
Oct 6, 2026 — VERA dips 1.4% to $29.42, a 1-month low, 8 down days in a row
- Closed at $29.42, -1.37% vs the prior close of $29.83. Day range $28.37–$30.10, opened at $29.98.
- Volume was 2.40M shares, 1.1x its 50-day average of 2.27M.
- Price is -10.5% vs its 50-day average ($32.85) and -24.2% vs its 200-day average ($38.83).
- 52-week range $23.05–$56.05; today's close sits at 19% of that range, 47.5% below the 52-week high.
- That makes 8 straight losses.
Oct 5, 2026 — VERA dips 1.9% to $29.83, a 1-month low, 7 down days in a row
- Closed at $29.83, -1.94% vs the prior close of $30.42. Day range $28.79–$30.74, opened at $30.58.
- Volume was 2.72M shares, 1.2x its 50-day average of 2.23M.
- Price is -9.5% vs its 50-day average ($32.97) and -23.4% vs its 200-day average ($38.93).
- 52-week range $23.05–$56.05; today's close sits at 21% of that range, 46.8% below the 52-week high.
- That makes 7 straight losses.
Oct 2, 2026 — VERA dips 1.8% to $30.42, a 1-month low, 6 down days in a row
- Closed at $30.42, -1.84% vs the prior close of $30.99. Day range $29.80–$31.27, opened at $31.16.
- Volume was 1.61M shares, 0.7x its 50-day average of 2.26M.
- Price is -8.0% vs its 50-day average ($33.08) and -22.0% vs its 200-day average ($39.02).
- 52-week range $23.05–$56.05; today's close sits at 22% of that range, 45.7% below the 52-week high.
- That makes 6 straight losses.
VERA bull case vs bear case (from the data)
- No clear positive signal in the price trend, filings or insider data right now.
- Price is -10.2% vs its 50-day average — short-term trend is down.
- Price is -23.4% vs its 200-day average — below the long-term trend line.
- Latest fiscal-year net income: loss of $299.62M.
- Insider selling outweighs buying: 25 sales vs 0 open-market buys among the 25 most recent reported insider trades (Form 4, last 12 months).
- Share count up 12.9% in a year (dilution).
VERA latest news & SEC filings
Every SEC filing by or about VERA in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Fordyce Marshall converted options/RSUs into 18,500 shares at $2.90 (≈$53.59K) on Sep 15, 2026; now holds 253,744
- Fordyce Marshall sold 18,500 shares at $37.00 (≈$684.50K) on Sep 15, 2026; now holds 235,244
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 15, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Sep 14, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 4, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Fordyce Marshall sold 18,500 shares at $35.12 (≈$649.72K) on Sep 2, 2026
- Fordyce Marshall sold 18,500 shares at $35.12 (≈$649.72K) on Sep 2, 2026
- Fordyce Marshall sold 18,500 shares at $35.12 (≈$649.72K) on Sep 2, 2026
- Fordyce Marshall sold 18,500 shares at $35.12 (≈$649.72K) on Sep 2, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 2, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form 4/A — Insider trade (amended)
Amended insider trade report (Form 4/A)
- Fordyce Marshall sold 1,000 shares at $40.78 (≈$40.78K) on Jul 7, 2026
- Fordyce Marshall sold 2,200 shares at $43.59 (≈$95.90K) on Jul 7, 2026
- Fordyce Marshall sold 10,500 shares at $42.86 (≈$450.03K) on Jul 7, 2026
- Fordyce Marshall sold 32,550 shares at $42.07 (≈$1.37M) on Jul 7, 2026
- Fordyce Marshall sold 1,000 shares at $40.78 (≈$40.78K) on Jul 7, 2026
- Fordyce Marshall sold 2,200 shares at $43.59 (≈$95.90K) on Jul 7, 2026
- …plus 10 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 12, 2026 · Form 4/A — Insider trade (amended)
Amended insider trade report (Form 4/A)
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 10, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$109.47M (prior year -$76.53M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$1.52 (prior year -$1.20) (loss widened vs Jun 30, 2025)
Aug 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 7, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 30, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 9, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Jul 7, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade VERA
- Last results release: Aug 10, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Feb 26, 2026, Nov 5, 2025. Based on that rhythm, the next report is likely around Nov 9, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.84% (largest 8.9%).
- Liquidity: about 1.77M shares (≈$51.23M) trade per day on average.
- 52-week position: $28.92 vs a range of $23.05–$56.05 (18% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Marshall Fordyce sold 18,500 shares on Sep 15, 2026.
- Latest filings: 8-K Sep 15, 2026; 10-Q Aug 10, 2026; 8-K Aug 10, 2026.
- Share count: 72.06M shares outstanding (Jul 29, 2026), +12.9% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
VERA market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 19, 2026 | 28.18 | 29.23 | 27.61 | 28.92 | 1.27M |
| Oct 16, 2026 | 28.30 | 28.40 | 27.50 | 27.88 | 1.29M |
| Oct 15, 2026 | 27.28 | 28.83 | 27.13 | 28.57 | 1.53M |
| Oct 14, 2026 | 26.84 | 27.42 | 26.38 | 26.74 | 1.53M |
| Oct 13, 2026 | 27.62 | 27.73 | 26.55 | 26.79 | 2.99M |
| Oct 12, 2026 | 29.11 | 29.49 | 27.64 | 27.72 | 1.41M |
| Oct 9, 2026 | 29.57 | 30.51 | 29.46 | 29.88 | 996.60K |
| Oct 8, 2026 | 30.00 | 30.25 | 28.74 | 29.73 | 1.73M |
| Oct 7, 2026 | 29.09 | 30.61 | 28.46 | 30.25 | 3.29M |
| Oct 6, 2026 | 29.98 | 30.10 | 28.37 | 29.42 | 2.40M |
| Oct 5, 2026 | 30.58 | 30.74 | 28.79 | 29.83 | 2.72M |
| Oct 2, 2026 | 31.16 | 31.27 | 29.80 | 30.42 | 1.61M |
| Oct 1, 2026 | 32.14 | 32.44 | 30.87 | 30.99 | 1.01M |
| Sep 30, 2026 | 32.57 | 33.60 | 32.20 | 32.29 | 1.80M |
| Sep 29, 2026 | 32.50 | 32.84 | 31.90 | 32.38 | 1.46M |
| Sep 28, 2026 | 32.34 | 33.04 | 31.42 | 32.50 | 1.46M |
| Sep 25, 2026 | 33.34 | 33.44 | 32.46 | 32.54 | 1.25M |
| Sep 24, 2026 | 32.72 | 33.68 | 32.23 | 33.34 | 1.69M |
| Sep 23, 2026 | 36.27 | 36.50 | 32.63 | 33.05 | 2.02M |
| Sep 22, 2026 | 34.67 | 36.50 | 34.29 | 36.26 | 1.98M |
About Vera Therapeutics
Vera Therapeutics (VERA) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in BRISBANE, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1831828.
VERA board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Andrew Cheng | Director | May 26, 2026 |
| Patrick G Enright | Director | May 26, 2026 |
| Marshall Fordyce | PRESIDENT AND CEO | Sep 17, 2026 |
| Kimball Hall | Director | May 26, 2026 |
| Christopher Hite | Director | Mar 9, 2026 |
| Michael Morrissey | Director | May 26, 2026 |
| James R Meyers | Director | May 26, 2026 |
| Scott W Morrison | Director | May 26, 2026 |
| Christy J. Oliger | Director | May 26, 2026 |
| Beth C Seidenberg | Director | May 26, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Nancy Lee Boman | Chief Regulatory Officer | Aug 5, 2026 |
| Robert Brenner | Chief Medical Officer | Feb 25, 2026 |
| Jason S Carter | Chief Legal Officer | Nov 25, 2025 |
| Marshall Fordyce | PRESIDENT AND CEO | Sep 17, 2026 |
| Sean Grant | CHIEF FINANCIAL OFFICER | Feb 25, 2026 |
| David Lee Johnson | Chief Operating Officer | Feb 25, 2026 |
| Laurence Matthew Skelton | Chief Commercial Officer | Feb 25, 2026 |
| William D. Turner | Chief Regulatory Officer | Feb 25, 2026 |
| Jane Wright-Mitchell | Chief Legal Officer | Mar 25, 2026 |
| Joseph R Young | SVP, FINANCE, CHIEF ACCT OFFCR | Sep 14, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 15, 2026 | Marshall Fordyce | Sale | 18,500 | $37.00 |
| Sep 15, 2026 | Marshall Fordyce | Sale | 18,500 | $37.00 |
| Sep 15, 2026 | Marshall Fordyce | Sale | 18,500 | $37.00 |
| Sep 15, 2026 | Marshall Fordyce | Sale | 18,500 | $37.00 |
| Sep 2, 2026 | Marshall Fordyce | Sale | 18,500 | $35.12 |
| Sep 2, 2026 | Marshall Fordyce | Sale | 18,500 | $35.12 |
| Sep 2, 2026 | Marshall Fordyce | Sale | 18,500 | $35.12 |
| Sep 2, 2026 | Marshall Fordyce | Sale | 18,500 | $35.12 |
| Jul 7, 2026 | Marshall Fordyce | Sale | 1,000 | $40.78 |
| Jul 7, 2026 | Marshall Fordyce | Sale | 2,200 | $43.59 |
| Jul 7, 2026 | Marshall Fordyce | Sale | 10,500 | $42.86 |
| Jul 7, 2026 | Marshall Fordyce | Sale | 32,550 | $42.07 |
| Jul 7, 2026 | Marshall Fordyce | Sale | 1,000 | $40.78 |
| Jul 7, 2026 | Marshall Fordyce | Sale | 2,200 | $43.59 |
| Jul 7, 2026 | Marshall Fordyce | Sale | 10,500 | $42.86 |
VERA financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-299.62M | -4.66 | $-241.10M |
| Dec 31, 2024 | — | $-152.15M | -2.75 | $-134.68M |
| Dec 31, 2023 | — | $-95.99M | -2.25 | $-92.18M |
| Dec 31, 2022 | — | $-89.06M | -3.35 | $-67.60M |
| Dec 31, 2021 | — | $-32.61M | -2.43 | $-23.71M |
Latest balance sheet: total assets $532.98M, total liabilities $125.23M, cash $48.88M (as of Jun 30, 2026).
VERA earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 10, 2026 | 8-K Item 2.02 (results) | $31.58 |
| May 7, 2026 | 8-K Item 2.02 (results) | $35.88 |
| Feb 26, 2026 | 8-K Item 2.02 (results) | $42.35 |
| Nov 5, 2025 | 8-K Item 2.02 (results) | $24.10 |
| Aug 5, 2025 | 8-K Item 2.02 (results) | $20.64 |
| May 6, 2025 | 8-K Item 2.02 (results) | $22.01 |
| Feb 26, 2025 | 8-K Item 2.02 (results) | $27.77 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $49.04 |
| Oct 28, 2024 | 8-K Item 2.02 (results) | $47.34 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
| Mar 20, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Regeneron Pharmaceuticals (REGN)Novo Nordisk A S (NVO)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)AMD (AMD)Microsoft (MSFT)Intel (INTC)Amazon (AMZN)
More on VERA
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 19, 2026, 4:00 PM ET. Filings: SEC EDGAR. Refreshed every 2 hours during US market hours.